Beijing Tongrentang: Revenue and profit contracted, while cost controls and positive cash flow offered some supportQuartr·Oct 30, 2026 at 09:49 AM600085-0.75%
Beijing Tongrentang: Revenue and profit fell sharply year-over-year, but R&D and global expansion acceleratedQuartr·Aug 30, 2026 at 06:09 PM600085-0.75%
Tong Ren Tang Technologies signs new e-commerce services deal with Tong Ren Tang Shuzi Technology through 2028PUBT·Aug 28, 2026 at 11:18 AM01666-1.51%600085-0.75%
Tong Ren Tang Technologies schedules board meeting on interim results, dividend decisionPUBT·Aug 14, 2026 at 08:45 AM01666-1.51%600085-0.75%
New Progress in Centralized Procurement of Chinese Herbal Pieces: 41 Varieties Included, 300 Billion Market Landscape to ChangeWallstreetcn·Apr 14, 2026 at 12:17 PM01666-1.51%00570-1.76%
In the "Performance" report, TONG REN TANG announced a full-year net profit of 396 million RMB, a decrease of 24.1%, with a final dividend of 18 centsAASTOCKS·Mar 29, 2026 at 05:21 AM01666-1.51%600085-0.75%
4 New stocks in the dark market "report success" with DeShi showing double profits, while HuaYan Robotics only rises by 10%Stheadline·Mar 28, 2026 at 01:26 AM03613-0.36%600085-0.75%
Tongrentang Medical and Health has opened its IPO: plans to raise HKD 900 million and list on March 30, with a 10% decline in profits over 9 months雷帝触网·Mar 23, 2026 at 12:30 PM600085-0.75%03613-0.36%
TRT launches IPO to provide medical and health services relying on its time-honored brandBambooWorks·Mar 23, 2026 at 07:10 AM01666-1.51%600085-0.75%
【New Stock IPO】【Subscription Situation】【Continuously Updated】Traditional Chinese Medicine Healthcare Service Industry Tong Ren Tang Medical Care (2667) received HKD 250 million in margin financing, with an oversubscription of 1.8 timesTasty Money·Mar 23, 2026 at 02:54 AM600085-0.75%01666-1.51%
Tong Ren Tang Subsidiary Posts Lower 2025 Profit as Revenue and Margins DeclineTip Ranks·Mar 20, 2026 at 01:41 PM600085-0.75%03613-0.36%
Beijing Tong Ren Tang Chinese Medicine Sets HKD 0.37 Final Dividend for 2025Tip Ranks·Mar 20, 2026 at 01:10 PM600085-0.75%
Chinese Medicine Firm Seeks Elusive Elixir Of IPO Successbenzinga_article·Feb 5, 2026 at 07:11 PM01666-1.51%600085-0.75%
With only six months left until July 1, 2026, the implementation of Article 75 of the National Medical Products Administration's "Special Regulations on the Registration of Traditional Chinese Medicine" is entering its final window period. This regulation, referred to in the industry as the "death clause" for proprietary Chinese medicines, clearly states that after three years of implementation starting from July 1, 2023, the contraindications in the instructions will be prohibitedWallstreetcn·Jan 27, 2026 at 10:41 AM512290-1.79%159929-0.99%
